Home
This site is intended for healthcare professionals

Precision Decisions in Metastatic Prostate Cancer: Module 2 Targeting Applying PARPi evidence to treatment decisions

Share

Description

This program is supported by an independent education grant from Pfizer. This education program is only available to healthcare professionals in the USA.

Credits: AMA PRA Category 1 Credits™ (0.25.00 hours)

Type of activity: Enduring material (On-demand)

Launch date: September 16th 2026

Expiration date: December 31st 2027

Estimated time to complete this activity: 15 minutes

Prefer to read instead? Read our Key Clinical Summary here.

This is Module 2 of a three-part on-demand series: Module 1 and Module 3.

Activity Description

Join expert Dr. Alicia Morgans, MD, MPH, for a practical, case-based exploration of how to translate PARP inhibitor clinical trial evidence into targeted treatment decisions for patients with metastatic prostate cancer. This session unpacks the biological rationale of synthetic lethality when combining PARP and androgen receptor (AR) pathway inhibition, guiding clinicians through the complex landscape of PARP inhibitor approvals across disease states. Through real-world clinical cases, participants will learn how to weigh the profound efficacy seen in BRCA-altered disease against the more nuanced data in non-BRCA homologous recombination repair (HRR) alterations, manage regimen-specific toxicities, and determine the optimal sequencing of targeted therapies.

Session Highlights

  • Understand the biological mechanism of AR-PARP crosstalk and how AR inhibition can induce a BRCA-like state, providing the rationale for combination therapy.
  • Evaluate key trial data (including PROpel, MAGNITUDE, and TALAPRO-2) to navigate the crucial gap between broad clinical trial populations and the narrower, biomarker-specific FDA-approved indications.
  • Proactively manage regimen-specific adverse events, particularly grade 3–4 anemia, by utilizing appropriate dose modifications to maintain treatment continuity.
  • Assess the clinical trade-offs of using upfront PARP inhibitor combinations versus reserving monotherapy for later lines, taking into account the significant risk of patient attrition as the disease progresses.

Who Should Participate?

This program is designed for healthcare professionals directly involved in the diagnosis, targeted treatment, and longitudinal management of patients with metastatic prostate cancer (mPC), who seek to implement guideline-concordant genomic testing and multidisciplinary care into routine clinical practice.

  • Oncology and Urology Practitioners (Academic and Community)
  • Oncology Nurses
  • Nurse Practitioners
  • Physician Assistants
  • Pharmacists
  • Genetic Counselors
  • Other Healthcare Professionals involved in the care and treatment of patients with mPC

Faculty

Dr Alicia Morgans

Dr Alicia Morgans is a Genitourinary Medical Oncologist and Director of the Survivorship Program at Dana-Farber Cancer Institute. Her clinical and research expertise focuses on improving outcomes and quality of life for men living with prostate cancer. Her research explores the long-term complications of systemic therapy, including skeletal, cardiovascular, metabolic, and cognitive effects, while incorporating patient-reported outcomes, preferences, and beliefs into clinical decision-making. Dr Morgans is also actively involved in prostate cancer treatment guidelines and survivorship initiatives, supporting more personalized, patient-centered approaches to care..

Continuing Education Information

Commercial support: This activity received monetary support through an independent education grant from Pfizer.

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Disclosures

Dr Alicia Morgans has disclosed financial relationships within the past 24 months with the following ineligible companies: Consultant: AstraZeneca, Astellas, Bayer, Curium, Exelixis, Janssen, Lantheus, Macrogenics, Merck, Novartis, Pfizer, Telix, Tolmar, Sanofi, and Sumitomo Pharma America, Inc.; and receiving grant/research support from Astellas, Bayer, Janssen, Pfizer, Sumitomo Pharma America, Inc.

These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education.

Dr Morgans does not intend to discuss non-FDA uses of drug products and/or devices only in relation to products for which he has no financial relationships.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible companies. All relevant financial relationships for anyone associated with the content of this activity were mitigated prior to the release of this program.

Activity Accreditation for Health Professions

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

  • When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
  • Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

Participation Costs

There is no cost to participate in this program.

This continuing education activity is active starting September 16th 2026, and will expire on December 31st 2027..

Estimated time to complete this activity: 15 minutes.

Learning objectives

By the end of this education. HCPs will be able to:

Implement standardized, guideline-concordant HRR biomarker testing workflows in patients with mPC:

  • Identify patients eligible for germline and somatic HRR testing, including non-BRCA mutations.
  • Determine appropriate timing and testing modality within the clinical pathway.
  • Interpret test results to inform eligibility for targeted therapies within real-world workflows.

Apply emerging clinical evidence on PARPi-based therapies to guide treatment selection and sequencing in mPC:

  • Interpret clinical data on efficacy, safety, and biological rationale for PARPi-based combination strategies.
  • Select appropriate patients for PARPi combination strategies across mCSPC and mCRPC.
  • Determine optimal sequencing of therapies based on disease stage, biomarkers, and patient factors.

Manage treatment-related toxicities and coordinate multidisciplinary care for patients receiving PARPi-based therapies:

  • Identify and mitigate common hematologic and gastrointestinal adverse events (AEs) associated with PARPi combination therapies.
  • Apply dose modification and supportive care strategies to maintain treatment continuity in practice.
  • Coordinate multidisciplinary input to optimize safety, adherence, and patient outcomes.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

Hi, my name is Doctor Alicia Morgans, and I am a GU medical oncologist and the director of the Survivorship Program at Dana-Farber Cancer Institute in Boston, Massachusetts in the United States. Before I begin, I would love to share my disclosures. Today, we're going to be talking about precision decisions in metastatic prostate cancer, going through testing, targeting, and treating. So I'm excited to talk about that as specifically as it applies to PARP inhibitor evidence so that we can use that to support our treatment decisions. So let's start with the polling question. So here it is, which patient is most likely to derive substantial benefit from adding a PARP inhibitor to an ARPI? Is it A, a man with a BRCA2 alteration, B, a man with an ATM alteration, C, a man with no HRR alteration detected, or D, a man whose HRR status is unknown? The correct answer here is actually A, a man with a BRCA2 alteration, and we'll get into the evidence to support that. Luckily, this is the most common alteration that we see in patients with advanced prostate cancer, and being that it is also the most responsive to BRCA inhibition, it's actually just a wonderful fortuitous thing. So let's go to case vignette two. The report is back. What are we going to do? This patient, of course, is a patient with metastatic castration-resistant prostate cancer that has progressed after treatment with an AR pathway inhibitor. The patient is 71 years old and has a good ECOG performance status of 1. The patient has been treated with abiraterone and EDT for 19 months as we've seen, and PSA is rising. Over three months, from 4.1 to 11.6 up to 28 nanograms per milliliter. The patient does have radiographic progression with new osseous metastases and enlarging lymph nodes, and germline and somatic testing was sent at diagnosis, as is standard of care and is recommended by multiple guidelines. The somatic panel showed an ATM alteration with no BRCA1 or 2 alteration detected. Now, I think as I consider this, of course, we just discussed that a BRCA2 alteration may be the most responsive to PARP inhibition. And so the question, what did we hope it would say? Perhaps we hope that it would say that there was a BRCA2 alteration. What I do counsel my patients in this setting though, however, is that BRCA2 is associated with a more aggressive disease phenotype and sometimes a poorer prognosis. And so not having a BRCA2 alteration is actually also a good thing. And in this situation, we have an ATM alteration. At least we've identified and clarified the molecular status of our patient's cancer so that we can better understand. Does this particular ATM alteration change our, our regimen? And do we think about using it in combination with an AR pathway inhibitor or with a PARP inhibitor at some point in the future? Well, let's dig into the data to help us explain and understand that a little bit better. First, I think it's important that we remember and, and consider the concept of synthetic lethality or the biologic rationale for why we might want to combine a PARP inhibitor and an androgen receptor pathway inhibitor or ARPI in patients with prostate cancer. We know that the, um, these PARP proteins are typically involved in DNA repair. And as we can see, the PARP one acts as a co-activator of androgen receptor transcription. And at the same time, the androgen receptor, which we know drives the majority of prostate cancers, uh, also supports that transcription of DNA repair elements. So there's Very much a crosstalk between these two systems and these two pathways that these prostate cancer cells use for progression and spread. If we're able to block the androgen receptor and simultaneously induce a BRCA-S as an example, we can then come in with a PARP inhibitor and expect that we may have synergistic potentially or at least simultaneous activity against the cancer. Here we can see also that in an HR proficient cell, a PARP inhibitor is not supposed to be or expected to be active. But if the patient is an HR deficient cancer, a BRCA state or a BRCA-like state that may have been induced by AR inhibition, we know that PARP inhibitors can be highly effective and result in cell death due to the accumulation of uh DNA defects, uh, and, and things that are unable to be repaired. So ultimately, why do we combine these pathways? Because AR signaling supports transcription of DNA repair genes and blocking AR androgen receptor, can induce this BRCAness or BRCAlite state in HR proficient cells, and PARP1 can act as the co-activator of AR transcription. It's going both ways, so if we bring them together, we have a nice rationale. For inhibiting both pathways, even potentially in all comer populations. Importantly, PARP inhibitor monotherapy was and has been established as a treatment algorithm for people with advanced prostate cancer in the MCRPC or metastatic castration-resistant prostate cancer setting for actually many years at this point. It all started with the profound trial which looked at alarib versus the physician's choice of the alternate AR pathway inhibitor in patients with metastatic castration-resistant prostate cancer who had uh come in to the study as having these HRR mutations, either BRCA1, BRCA2, ATM or one of several other uh HRR alterations. And we found in that setting in this Elected population that a laparib as a single agent was able to prolong the time to radiographic progression-free survival and overall survival, particularly in the BRCA population, and this led to the establishment and the approval across the world in most countries, or many at least, of the use of elaparib as a single agent in patients with HRR mutations in the MCRPC setting. We also have the Triton 3 data, which looked at rucaporib in patients who have BRCA1, BRCA2, or ATM alterations with metastatic castration resistant prostate cancer. And these patients had had a prior AR pathway inhibitor as well, and were treated with either chemotherapy or the alternate AR pathway inhibitor. In this setting, rucapirib was also associated with the radiographic progression-free survival benefit that again was largest in the BRCA subgroup, but did not seem evident in the ATM subgroup. So this drug is approved for BRCA mutations only, uh, and actually only in a Post-chemotherapy, post-AIR pathway inhibitor, MCRPC setting. This may be relevant for our patient who has an ATM alteration as we're thinking through the expected benefits. And we can see at the bottom here, the differential benefit from olaporabin profound, um, from rucaprobin triton 3 in BRCA, as well as the ATM subgroup which also has quite a small effect there, does not seem to have a benefit. There are 5 combination trials that are, uh, have been performed in patients with metastatic castration resistant or metastatic castration sensitive or hormone-sensitive prostate cancer. And we can see that they're all listed here. Just to acknowledge that the nomenclature is also changing, so MCRPC is also at this point known as MAPMR and MCSPC is also at this point known as MAPMN or S. So, just so that we're not confused over time thinking through all of the new data, there are some different names for us to also consider. But if we start at the top, the Propel trial is a trial that combined laparib and abiraterone in first-line MCRPC for patients, all comers who could have had or did not have HRR alterations, and the primary endpoint here was radiographic progression-free survival uh for patients treated with laparib and abiraterone versus abiraterone alone. They did find that there was an improvement in RPFS, the US data was not significant, but this was most pronounced in patients with BRCA mutations, which contributed to the US label, which is that this combination is approved in patients with MCRPC, um, who have BRCA mutations. I would say that the global label here is actually in, in many countries, a bit more broad and, and some places may include an all-comer label, so just to be aware of that. The magnitude study included patients with metastatic castration resistant prostate cancer also in the same first line setting. All patients in the in the trial that showed a benefit had HRR alterations, and in this setting, patients received narapirib and abiraterone versus abiraterone alone, and the is positive for the combination showing benefit in radiographic progression-free survival in the HRR cohort. Again, approved here but only approved for patients with BRCA mutations. Telapro 2 was approved, uh, was a study that was done in first-line MCRPC as well, so same setting. And in this study, patients had an all-comerce cohort as well as an HRR deficient cohort. So quite a large study. Everybody defined from the beginning in terms of their HRR status, and patients were treated with halazoperib plus enzalutamide or enzalutamide alone, and we found that the combination demonstrated an RPFS benefit, um, and OS as well.